Li et al.37reported that enzalutamide induces HR deficiency by suppressing the expression of BRCA1, RAD54L, and RMI2 in prostate cancer, thereby, enhancing the therapeutic effect of olaparib. Here, BRCA1 is linked to Familial prostate cancer.